GANX

Gain Therapeutics, Inc.

• TipRanks·05/14 13:55

  Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7

• TipRanks·05/13 13:06

  Gain Therapeutics (GANX) Gets a Buy from Oppenheimer

• TipRanks·05/12 19:29

  Gain Therapeutics price target lowered to $8 from $10 at Roth Capital

• TipRanks·05/12 10:50

  Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), Health Catalyst (HCAT) and Gain Therapeutics (GANX)

• Reuters·05/11 12:00

  Gain Therapeutics Q1 loss per share narrows

• TipRanks·05/11 11:47

  Gain Therapeutics reports Q1 EPS (13c), consensus (14c)

• Dow Jones·05/11 11:08

  *Gain Therapeutics: Expect to Receive FDA Clearance of Our GT-02287 IND During 2Q 2026 >GANX

• Dow Jones·05/11 11:08

  *Gain Therapeutics: Remain on Track to Begin Our Phase 2 Study in 3Q 2026 >GANX

• Dow Jones·05/11 11:07

  *Gain Therapeutics 1Q Loss/Shr 13c >GANX

• Seeking Alpha·05/11 11:06

  Gain Therapeutics GAAP EPS of -$0.13 beats by $0.01

• PUBT·05/11 11:04

  Gain Therapeutics Q1 FY26 net loss per share narrows to $0.13

• Reuters·05/11 11:00

  GAIN THERAPEUTICS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2026 AND PROVIDES CORPORATE UPDATE

• Dow Jones·05/11 11:00

  Press Release: Gain Therapeutics Reports -2-

• NASDAQ·04/24 18:50

  Gain To Present New Parkinson's Disease Data On GT-02287 At International GBA1 Meeting; Stock Up

• Benzinga·04/24 12:33

  Gain Therapeutics To Give Oral Presentation Update On GCase Modulator For Parkinson's Disease At 3rd International GBAI Meeting May 22-23